Scutellarein protects against cardiac hypertrophy via suppressing TRAF2/NF-κB signaling pathway

[1] Gupta S(2007)Cardiac hypertrophy: mechanisms and therapeutic opportunities Antioxid Redox Signal 9 623-652

[2] Das B(1999)Left ventricular hypertrophy in hypertension: stimuli, patterns, and consequences Hypertens Res 22 1-9

[3] Sen S(2004)Obligatory role for endogenous endothelin in mediating the hypertrophic effects of phenylephrine and angiotensin II in neonatal rat ventricular myocytes: evidence for two distinct mechanisms for endothelin regulation J Pharmacol Exp Ther 310 43-51

[4] Devereux RB(2003)Cardiac hypertrophy: the good, the bad, and the ugly Annu Rev Physiol 65 45-79

[5] Roman MJ(2014)Targeting cardiac hypertrophy: toward a causal heart failure therapy J Cardiovasc Pharmacol 64 293-305

[6] Xia Y(2015)Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets Arch Toxicol 89 1401-1438

[7] Karmazyn M(2001)The alpha and beta subunits of IkappaB kinase (IKK) mediate TRAF2-dependent IKK recruitment to tumor necrosis factor (TNF) receptor 1 in response to TNF Mol Cell Biol 21 3986-3994

[8] Frey N(2006)NF-kappa B activation as a pathological mechanism of septic shock and inflammation Am J Physiol Lung Cell Mol Physiol 290 L622-L645

[9] Olson EN(2012)Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy Heart 98 1007-1013

[10] Bisping E(1997)Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases N Engl J Med 336 1066-1071

[1] Gupta S(2007)Cardiac hypertrophy: mechanisms and therapeutic opportunities Antioxid Redox Signal 9 623-652

[2] Das B(1999)Left ventricular hypertrophy in hypertension: stimuli, patterns, and consequences Hypertens Res 22 1-9

[3] Sen S(2004)Obligatory role for endogenous endothelin in mediating the hypertrophic effects of phenylephrine and angiotensin II in neonatal rat ventricular myocytes: evidence for two distinct mechanisms for endothelin regulation J Pharmacol Exp Ther 310 43-51

[4] Devereux RB(2003)Cardiac hypertrophy: the good, the bad, and the ugly Annu Rev Physiol 65 45-79

[5] Roman MJ(2014)Targeting cardiac hypertrophy: toward a causal heart failure therapy J Cardiovasc Pharmacol 64 293-305

[6] Xia Y(2015)Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets Arch Toxicol 89 1401-1438

[7] Karmazyn M(2001)The alpha and beta subunits of IkappaB kinase (IKK) mediate TRAF2-dependent IKK recruitment to tumor necrosis factor (TNF) receptor 1 in response to TNF Mol Cell Biol 21 3986-3994

[8] Frey N(2006)NF-kappa B activation as a pathological mechanism of septic shock and inflammation Am J Physiol Lung Cell Mol Physiol 290 L622-L645

[9] Olson EN(2012)Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy Heart 98 1007-1013

[10] Bisping E(1997)Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases N Engl J Med 336 1066-1071